Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers, which ...
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...
ABP-102/CT-P72 represents Abpro’s first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE ...
BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today ...
Abpro, an integrated life science company at the forefront of synthetic biology, today announced a partnership with Essex Bio, a China-based biopharmaceutical company. Abpro and Essex will co-develop ...
Abpro Holdings, Inc., a biotechnology company focused on developing antibody therapies for severe diseases, has announced the departure of CEO Ian Chan. Miles Suk, the Board Chairman, expressed ...
Abpro is taking a second run at the public markets. Five years after pulling out of a planned IPO, the antibody specialist is back with a special purpose acquisition company, agreeing to combine with ...
WOBURN, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of its neutralizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results